Understanding PFIC: Diagnosis, Genetics, Treatment

Progressive familial intrahepatic cholestasis (PFIC) is a rare group of inherited cholestatic liver disorders caused by defects in bile formation, secretion, or transport. Although traditionally described as PFIC types 1, 2, and 3, the disease spectrum is now understood to be broader, with additional genetic forms identified over the past decade. Clinically, PFIC usually presents in infancy or childhood with cholestasis, jaundice, growth impairment, and severe pruritus, and in many patients it progresses to fibrosis, cirrhosis, liver failure, or the need for liver transplantation. Older reviews estimate incidence at roughly 1 in 50,000 to 1 in 100,000 births, though the true burden is likely underestimated because of historical underdiagnosis and evolving molecular classification.

For clinicians and pharmacists, PFIC is important not only because it is rare and severe, but also because its management has changed materially. In the past, treatment was largely supportive or surgical. More recently, ileal bile acid transporter (IBAT) inhibitors have introduced a mechanism-based pharmacologic option for some patients, especially those with debilitating cholestatic pruritus. At the same time, the field has become more genotype-driven, meaning that accurate diagnosis now has direct therapeutic implications.

What causes PFIC?

PFIC is fundamentally a disorder of hepatobiliary transport. In healthy physiology, bile acids are synthesized in the liver, secreted into bile canaliculi, released into the intestine, and then partly reabsorbed through the enterohepatic circulation. In PFIC, pathogenic variants disrupt proteins involved in bile acid export, phospholipid transport, membrane stability, or canalicular integrity. This leads to retention of bile constituents within the liver and progressive cholestatic injury.

The classic forms remain highly relevant. PFIC1 is associated with ATP8B1 mutations, PFIC2 with ABCB11 mutations affecting the bile salt export pump (BSEP), and PFIC3 with ABCB4 mutations affecting MDR3 phospholipid transport. Reviews also describe newer variants, including PFIC4 related to TJP2, PFIC5 related to NR1H4 encoding FXR, and MYO5B-related cholestatic disease, sometimes grouped within the broader PFIC spectrum. This expanded molecular landscape is one reason the old numeric classification, while still useful, no longer captures the full clinical heterogeneity of PFIC.

Clinical presentation and why pruritus matters

PFIC commonly presents with jaundice, hepatomegaly, growth failure, fat malabsorption, and fat-soluble vitamin deficiency. Among symptoms, pruritus is often the most distressing. In many children, the itch is severe, chronic, sleep-disrupting, and functionally disabling for both patients and caregivers. This is clinically important because pruritus is not a minor supportive-care issue in PFIC; it is often a central determinant of quality of life and a major driver of treatment escalation.

The phenotype can vary by genotype. PFIC1 and PFIC2 classically present with low or normal gamma-glutamyl transferase (GGT) cholestasis, whereas PFIC3 is typically associated with elevated GGT. That biochemical pattern remains a practical clue during initial work-up, even though it should not replace molecular confirmation. PFIC2 is often regarded as more aggressive, and some literature has also highlighted an increased risk of hepatocellular carcinoma in BSEP deficiency, which adds urgency to early recognition and specialist surveillance.

How is PFIC diagnosed today?

Diagnosis starts with suspicion in any infant or child with persistent cholestasis, especially when biliary obstruction and more common causes have been excluded. The work-up generally includes liver biochemistry, serum bile acids, coagulation profile, nutritional assessment, fat-soluble vitamin status, imaging, and sometimes liver histology. However, the modern direction of travel is clear: genetic testing is now regarded as the gold standard for PFIC diagnosis. That shift matters because genotype increasingly influences prognosis, counseling, and treatment selection.

From a practical standpoint, clinicians should think of diagnosis as both syndrome recognition and molecular confirmation. Biochemistry can suggest the pattern, histology can support the differential, and immunohistochemistry may occasionally help in selected cases, but next-generation sequencing panels have become central. The 2023 expert opinion paper emphasized the need for more standardized diagnosis, referral, and monitoring pathways in PFIC, reflecting both greater disease awareness and the arrival of effective drug therapy.

Traditional management before the IBAT era

Historically, PFIC management relied on nutritional support, fat-soluble vitamin replacement, symptom control, and—in selected patients—surgical interruption of enterohepatic circulation. Ursodeoxycholic acid may be used in some forms, particularly where cholestatic biochemistry and bile flow may improve, but response is variable and genotype-dependent. As disease progresses, children may ultimately require biliary diversion procedures or liver transplantation. Even now, transplantation remains definitive therapy for advanced disease, decompensation, or treatment-refractory progression.

Surgical biliary diversion has been an important bridge or alternative to transplantation in selected cases, especially in low-GGT PFIC. However, the evidence base is heterogeneous and not all patients respond. More recent reviews emphasize that despite progress with newer drugs, a substantial proportion of patients still do not achieve adequate control and may continue to require surgery or transplantation before adulthood.

IBAT inhibitors: mechanism and clinical relevance

A major therapeutic advance in PFIC has been the development of IBAT inhibitors, which reduce the reabsorption of bile acids in the terminal ileum and thereby interrupt the enterohepatic circulation. Mechanistically, this lowers the return of bile acids to the liver and can reduce the cholestatic burden driving symptoms such as pruritus. The two most prominent agents in this class for PFIC are odevixibat and maralixibat.

Odevixibat is approved in the European Union for PFIC in patients aged 6 months or older, and the U.S. label indicates use for pruritus in PFIC from 3 months of age. EMA materials summarize that in the pivotal study, odevixibat reduced serum bile acids and improved itching versus placebo, with gastrointestinal adverse events such as diarrhea, abdominal pain, and soft stools among the most common side effects. The phase 3 PEDFIC 1 study has been summarized in peer-reviewed sources as showing significant improvements in both pruritus and serum bile acids relative to placebo, and the agent is widely viewed as an important non-surgical pharmacologic option.

Maralixibat has also expanded the therapeutic landscape. The current U.S. label indicates maralixibat for cholestatic pruritus in PFIC in patients aged 5 years and older, with a limitation of use in a subgroup of PFIC2 patients with specific ABCB11 variants resulting in non-functional or absent BSEP protein. In the phase 3 MARCH-PFIC trial, maralixibat improved pruritus and biochemical predictors linked to native liver survival, including serum bile acids, versus placebo. Diarrhea was the most commonly reported adverse event.

Why genotype now matters even more

The move toward genotype-driven care is one of the most important practical developments in PFIC. Not every patient responds equally to IBAT inhibition, and specific genotypes may predict limited benefit. This is clearly reflected in U.S. prescribing information for both odevixibat and maralixibat, which note reduced expected efficacy in subgroups of PFIC2 patients with ABCB11 variants causing non-functional or absent BSEP protein. For pharmacists and prescribers, that means molecular diagnosis is no longer just confirmatory; it is increasingly part of treatment selection and expectation setting.

This also changes multidisciplinary care. Hepatologists, geneticists, pharmacists, dietitians, and transplant teams all have clearer roles. The pharmacist’s contribution includes reviewing drug interactions, monitoring gastrointestinal tolerability, considering adherence challenges in small children, watching for changes in vitamin status, and reinforcing the distinction between symptom improvement and broader disease control. The 2024 review on emerging drugs also makes an important point: although short-term efficacy is encouraging, long-term outcome data are still developing, and many patients remain only partial responders.

What should clinicians watch in practice?

In routine care, several questions are clinically useful. Has pruritus meaningfully improved? Are serum bile acids falling? Is the child sleeping better, growing better, and requiring fewer rescue measures? Are there ongoing signs of progressive liver disease despite symptom control? These are not interchangeable endpoints. A patient may feel better symptomatically and still require close hepatology follow-up for fibrosis progression, portal hypertension, or transplant planning.

Monitoring should also include liver biochemistry, bilirubin, nutritional parameters, and fat-soluble vitamin status. Because IBAT inhibition can alter bile acid handling and gastrointestinal function, clinicians should remain alert to diarrhea, abdominal discomfort, and nutritional consequences. Regulatory documents for maralixibat specifically flag hepatotoxicity, gastrointestinal adverse reactions, and fat-soluble vitamin deficiency in the safety sections, reinforcing the need for structured monitoring rather than symptom-only follow-up.

Where is PFIC care heading?

PFIC management is moving from a mainly supportive and surgical model toward a precision rare-disease model built around earlier genetic diagnosis, targeted pharmacology, and closer longitudinal monitoring. Reviews from 2024 and 2025 suggest the field is likely to keep expanding, with continued work on better genotype-phenotype correlations, longer-term data for IBAT inhibitors, and exploration of other therapeutic strategies that may reduce bile acid synthesis, alter bile composition, or improve hepatocellular transport.

For PharmAnt readers, the key message is simple: PFIC is no longer a disease defined only by early liver failure and transplantation. It remains severe and heterogeneous, but it is now increasingly diagnosable at the molecular level and increasingly manageable with mechanism-based therapy in selected patients. The challenge ahead is to translate those advances into earlier recognition, more personalized treatment, and better long-term liver outcomes.

References (Vancouver)

1. Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014;4(1):25-36.
2. Jones-Hughes T, Dixon S, Fox D, et al. Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic literature review. Orphanet J Rare Dis. 2021;16:126.
3. McKiernan P, Baumann U, Fischler B, et al. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis. JHEP Rep. 2024;6:100949.
4. Amer S, Hajira A, Lam-Himlin D, et al. A comprehensive review of progressive familial intrahepatic cholestasis. World J Hepatol. 2014;6(2):112-8.
5. Vinayagamoorthy V, Srivastava A, Sarma MS. Newer variants of progressive familial intrahepatic cholestasis. World J Hepatol. 2021;13(12):2024-2038.
6. Gunaydin M, Bozkurter Cil AT. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med. 2018;10:95-104.
7. Thompson RJ, Arnell H, Artan R, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830-842.
8. Miethke AG, Thompson RJ, Arnell H, et al. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(7):615-628.
9. Hof WFJ, Oude Elferink RPJ, Beuers U, et al. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials. Expert Opin Emerg Drugs. 2024;29(2):119-132.
10. Hüpper MN, van Wessel DBE, Verkade HJ, et al. Surgical versus medical management of progressive familial intrahepatic cholestasis and effect on native liver survival: a systematic review. Children (Basel). 2023;10(6):1046.